S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

DISEASE CHARACTERISTICS: Diagnosis of hepatic metastases secondary to colorectal cancer by percutaneous hepatic biopsy Resectable hepatic metastases by any of the following: Minor resection (i.e., less than a hemihepatectomy) Major resection (i.e., hemihepatectomy or extended hepatectomy) Bilobar resection (including atypical resection) Synchronous primary tumor and hepatic metastases allowed Radiologic evidence of hepatic metastases by multiphasic contrast-enhanced spiral CT scan Resectable primary colorectal cancer that is in place allowed Measurable disease No evidence of extrahepatic metastases by chest x-ray or CT scan of the chest PATIENT CHARACTERISTICS: Age 18 and over Performance status Zubrod 0-1 Life expectancy Not specified Hematopoietic Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 2 times upper limit of normal (ULN) SGOT or SGPT ≤ 2.5 times ULN Renal Creatinine clearance ≥ 60 mL/min Urine protein/creatinine ratio < 1 OR Urine protein < 1 g by 24-hour urine collection Cardiovascular No uncontrolled hypertension (i.e., blood pressure > 150/90 mm Hg) History of hypertension allowed provided it is well controlled on a stable regimen of anti-hypertensive therapy No arterial thromboembolic event within the past 12 months, including any of the following: Transient ischemic attack Cerebrovascular accident Unstable angina Myocardial infarction No peripheral vascular disease ≥ grade 2 Other Not pregnant or nursing Fertile patients must use effective contraception No pre-existing peripheral neuropathy ≥ grade 2 No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy More than 6 months since prior adjuvant chemotherapy for the primary tumor No prior systemic chemotherapy for metastatic disease No prior hepatic artery infusion chemotherapy for metastatic disease Endocrine therapy Not specified Radiotherapy No prior radiotherapy for metastatic disease Surgery More than 7 days since prior colonoscopy or fine needle aspiration More than 28 days since prior major invasive surgery or open biopsy Other At least 4 weeks since prior and no concurrent sorivudine or brivudine No prior radiofrequency ablation for metastatic disease No prior cryotherapy for metastatic disease No other prior ablative techniques for metastatic disease No concurrent cimetidine Concurrent ranitidine or other drug from a different antiulcer class allowed No concurrent oral anticoagulation for treatment of thrombosis Concurrent warfarin (1 mg) to maintain patency of central venous catheter allowed